Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases

Nakashima, Rumi; Kamei, Satoshi; Fujikawa, Haruka; Ueno-Shuto, Keiko; Kawakami, Taisei; Eto, Yuka; Suico, Mary Ann; Li, Jian Dong; Kai, Hirofumi; Shuto, Tsuyoshi

doi:10.1016/j.bbrc.2020.01.081

Cited by 7 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, their potential benefits should also be balanced, given that these drugs have anti-inflammatory actions and protective effects on the lung, and could be effective against COVID-19. 41 , 42 …”

Section: Implications For Medications and Therapymentioning

confidence: 99%

“…GLP-1 receptor agonists 22,41,42 Anti-inflammatory effects; improves endothelial dysfunction; improves cardiovascular and renal functions Reduces appetite and increases satiety; gastrointestinal symptoms DPP-4 inhibitors 40,43,44 Blocks virus uptake; reduces inflammatory response; well tolerated Increases mortality in older patients (likely due to confounding by indication)…”

Section: Risk Of Dehydration Diabetic Ketoacidosis and Acute Kidney Injurymentioning

confidence: 99%

“…However, their potential benefits should also be balanced, given that these drugs have antiinflammatory actions and protective effects on the lung, and could be effective against COVID-19. 41,42 To reduce cytokine release in patients with moderateto-severe COVID-19, IL-6 receptor blockade with tocilizumab is used. 121 This treatment has been reported to have a positive effect on insulin resistance and insulin sensitivity.…”

Section: Reviewmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 and metabolic disease: mechanisms and clinical management

Steenblock

Schwarz

Ludwig

et al. 2021

The Lancet Diabetes & Endocrinology

185

160

View full text Add to dashboard Cite

Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.

show abstract

Section: Implications For Medications and Therapymentioning

confidence: 99%

Section: Risk Of Dehydration Diabetic Ketoacidosis and Acute Kidney Injurymentioning

confidence: 99%

Section: Reviewmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 and metabolic disease: mechanisms and clinical management

Steenblock

Schwarz

Ludwig

et al. 2021

The Lancet Diabetes & Endocrinology

185

160

View full text Add to dashboard Cite

show abstract

“…That said, it remains unclear whether GLP-1R agonists improve lung compliance. Various studies have reported contradictory findings regarding the effect of GLP-1R agonists on decreasing mucus or increasing surfactant production [4,15,23,24]. In mouse models of ALI, GLP-1R agonists blunted the reduction of surfactant in response to LPS administration [25][26][27].…”

Section: Structural Modificationmentioning

confidence: 99%

The GLP-1 receptor in airway inflammation in asthma: a promising novel target?

Peebles

2021

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

“…Da GLP-1RA anti-inflammatorisch wirken und protektive Effekte für die Lunge aufweisen, könnten sie durchaus relevant bei der Behandlung von COVID-19-Infektionen sein. Für die nähere Evaluierung eventueller Einsatzmöglichkeiten müssen weitere Studien durchgeführt werden 65 , 66 .…”

Section: Hintergrundunclassified

Management von Diabetespatienten in der COVID-19-Pandemie

et al. 2022

View full text Add to dashboard Cite

ZUSAMMENFASSUNGÜber 10 % der deutschen Bevölkerung leiden an metabolischen Krankheiten wie Diabetes, Adipositas, oder nicht alkoholischer Steatohepatitis. Betroffene sind während der COVID-19-Pandemie einem besonderen Risiko ausgesetzt, gibt es doch zahlreiche Hinweise auf eine bidirektionale Beziehung zwischen diesen Krankheiten und COVID-19. Einerseits besteht ein deutlich erhöhtes Risiko für das Auftreten schwerer Krankheitsverläufe bis hin zum Tod, andererseits kann eine COVID-19-Infektion bereits bestehende metabolische Störungen verschlimmern oder neu hervorrufen. Wir werden hier die aktuelle Datenlage bezüglich der pathophysiologischen Mechanismen, die zu dieser bidirektionalen Beziehung führen, zusammenfassen und Empfehlungen für den Umgang mit solchen Patienten während und nach einer Infektion aussprechen.

show abstract

Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases

Cited by 7 publications

References 33 publications

COVID-19 and metabolic disease: mechanisms and clinical management

COVID-19 and metabolic disease: mechanisms and clinical management

The GLP-1 receptor in airway inflammation in asthma: a promising novel target?

Management von Diabetespatienten in der COVID-19-Pandemie

Contact Info

Product

Resources

About